Scinai Immunotherapeutics Holds Annual Shareholder Meeting
Ticker: SCNI · Form: 6-K · Filed: Nov 22, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Nov 22, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-actions, company-update
Related Tickers: SCNI
TL;DR
Scinai Immunotherapeutics (SCNI) held its annual shareholder meeting on Nov 21, 2024, with over 3.4B shares eligible to vote.
AI Summary
On November 21, 2024, Scinai Immunotherapeutics Ltd. held its Annual Meeting of Shareholders. The total number of ordinary shares eligible to vote was 3,411,983,584. The company previously operated under the name BiondVax Pharmaceuticals Ltd. before changing it on June 24, 2014.
Why It Matters
This filing confirms the company's operational status and provides key details about its shareholder structure as of the meeting date.
Risk Assessment
Risk Level: low — This is a routine administrative filing confirming a shareholder meeting and share count, with no new financial or operational developments.
Key Numbers
- 3,411,983,584 — Ordinary Shares (Total number of shares entitled to vote at the Annual Meeting of Shareholders on November 21, 2024.)
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- BiondVax Pharmaceuticals Ltd. (company) — Former company name
- 3,411,983,584 (dollar_amount) — Ordinary shares entitled to vote
- November 21, 2024 (date) — Annual Meeting of Shareholders date
- June 24, 2014 (date) — Date of name change from BiondVax Pharmaceuticals Ltd.
FAQ
What was the purpose of the Form 6-K filing?
The Form 6-K filing was to report on the Annual Meeting of Shareholders held by Scinai Immunotherapeutics Ltd. on November 21, 2024.
How many ordinary shares were eligible to vote at the meeting?
There were 3,411,983,584 Ordinary Shares entitled to vote at the meeting.
When did Scinai Immunotherapeutics Ltd. change its name?
The company changed its name from BiondVax Pharmaceuticals Ltd. on June 24, 2014.
What is the company's principal executive office address?
The company's principal executive office is located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.
Does the company file annual reports under Form 20-F or 40-F?
The registrant indicates it files annual reports under Form 20-F.
Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 15.7 · Accepted 2024-11-22 08:38:56
Filing Documents
- ea0222250-6k_scinai.htm (6-K) — 29KB
- 0001213900-24-101231.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Scinai Immunotherapeutics Ltd November 22, 2024 /s/ Amir Reichman Amir Reichman Chief Executive Officer 3